“Once a tried-and-true [COVID-19] vaccine is developed and subsequently incorporated as standard fare in medical practice, one driver of biotech will be mergers and acquisitions,” advises the author of today’s article. He proceeds to highlight an ETF that could benefit from this particular driving force – a fund that has generated a 30% return this year. For more, CLICK HERE.
Mergers And Acquisitions Will Drive Biotech Post-Vaccine – And This ETF Could Benefit
Tags:30% ReturnsAcquisitionsBiotech StocksCOVID-19 PandemicETFFundsInvestInvestingMergersStock Market